Denali Therapeutics Inc. (DNLI) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -511.45M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-511.45M | (m) |
| 2026-03-31 | (m) | $-508.02M | (m) |
| 2025-12-31 | (m) | $-512.54M | (m) |
| 2025-09-30 | (m) | $-498.74M | (m) |
| 2025-06-30 | (m) | $-479.03M | (m) |
| 2025-03-31 | (m) | $-453.94M | (m) |
| 2024-12-31 | (m) | $-422.77M | (m) |
| 2024-09-30 | (m) | $-427.49M | (m) |
| 2024-06-30 | (m) | $-419.65M | (m) |
| 2024-03-31 | (m) | $-137.25M | (m) |
| 2023-12-31 | (m) | $-145.22M | (m) |
| 2023-09-30 | (m) | $-124.43M | (m) |
| 2023-06-30 | (m) | $-128.38M | (m) |
| 2023-03-31 | (m) | $-370.55M | (m) |
| 2022-12-31 | (m) | $-325.99M | (m) |
| 2022-09-30 | (m) | $-302.57M | (m) |
| 2022-06-30 | (m) | $-283.86M | (m) |
| 2022-03-31 | (m) | $-285.76M | (m) |
| 2021-12-31 | (m) | $-290.58M | (m) |
| 2021-09-30 | (m) | $29.57M | (m) |
| 2021-06-30 | (m) | $55.92M | (m) |
| 2021-03-31 | (m) | $57.86M | (m) |
| 2020-12-31 | (m) | $71.14M | (m) |
| 2020-09-30 | (m) | $-227.77M | (m) |
| 2020-06-30 | (m) | $-215.81M | (m) |
| 2020-03-31 | (m) | $-215.38M | (m) |
| 2019-12-31 | (m) | $-197.61M | (m) |
| 2019-09-30 | (m) | $-66.06M | (m) |
| 2019-06-30 | (m) | $-55.17M | (m) |
| 2019-03-31 | (m) | $-51.55M | (m) |
| 2018-12-31 | (m) | $-36.24M | (m) |
| 2018-09-30 | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) |
| 2017-12-31 | (m) | $-88.19M | (m) |
| 2017-09-30 | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) |
| 2016-12-31 | (m) | $-86.65M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |